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whichwere isolated from the patients presentedwith enteric fever
during 1990 to 2015. Antimicrobial susceptibility testing was done
by disk diffusion method as per CLSI 2015 and MICs were deter-
mined by E test method as per manufacturer’s guidelines (AB
Biodisk, Sweden).
For molecular chaeacterization of azithromycin resistance, PCR
detection was done to screen for the presence of genes responsible
for azithromycin resistance i.e, ereA, ereB, ermB, mefA, mphA, mphB
and mphD from plasmid and genomic DNA. Sequence analysis was
done to detect mutations in acrR, rlpD and rlpV from genomic DNA.
Results: It was observed that 96.11% of the isolates were sus-
ceptible to azithromycin using disk diffusion method. There was
a linear trend observed with time in azithromycin susceptibility
(2 =5.240, P value <0.02). The MIC 50 and MIC 90 values were
6 and 12g/ml respectively while the resistance breakpoint is
≥16g/ml. There was no acquired gene for macrolide resistance
in plasmid or genomic DNA of any isolate and DNA sequences of
acrR, rlpD and rlpV genes did not show any mutations.
Total use of azithromycin in pediatric population was only
13,125 mg given to 16 patients in 2014-15.
Conclusion: Azithromycin is a good promising agent against
typhoid fever on the basis of MIC distribution in India at present.
More studies are required to study the use of azithromycin in
complicated infections as at present it is beingusedonly for uncom-
plicated cases.
http://dx.doi.org/10.1016/j.ijid.2016.02.316
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Background: Compound A is a novel Topo-IV inhibitor with
broad spectrum activity against both Gram- negative and posi-
tive pathogens, especially Pseudomonas aeruginosa, Acinetobacter.
baumannii, Escherichia coli, and MRSA. The present study focuses
on its in vitro activity, in vivo efﬁcacy and pharmacokinetics-
pharmacodynamics in murine infection models.
Methods & Materials: MIC were determined by CLSI method
against 135 bacterial strains including ATCC and clinical isolates of
(sensitive and MDR) Pseudomonas aeruginosa (n=55), A. baumannii
(n=25), Escherichia coli (n=30) andMRSA (n=25) includingMDR iso-
lates. Time kill study was performed against these pathogens. The
therapeutic efﬁcacywas evaluated using amouse pulmonary infec-
tion model. The pharmacokinetics-pharmacodynamics (PK-PD)
parameters against P. aeruginosa were determined in neutropenic
murine thigh infection model.
Results: Compound A showed MIC90 of 4, 0.5, 0.25 and 0.25
g/ml against P. aeruginosa, A. baumannii, E. coli and MRSA, respec-
tively. In murine pulmonary infection model, it showed killing
potential against P. aeruginosa and A. baumannii and reduced the
pulmonary bacterial number in a dose-dependent manner. In the
PK-PDstudy, theefﬁcacyofCompoundAagainstP. aeruginosa infec-
tion was correlated with AUC/MIC (R2 =0.89) and Time above MIC
(R2 = 0.93) more than Cmax/MIC (R2 =0.12).
Conclusion: Compound A exhibited excellent broad spectrum
of activity against Gram- positive and negative pathogens. Hence,
it could be a promising investigational candidate for antibacterial
therapy.
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Background: The emergence of bacterial resistance to antibi-
otics is a major concern; therefore, it is critical to develop new
antibiotics with novel modes of action. FtsZ is an essential bac-
terial guanosine triphosphatase (GTPase) play an essential role in
bacterial cell division, and its homologs are present in almost all
eubacteria, archaea and mammalian that polymerizes and assem-
bles into a ring to initiate cell division. Compound-A is a novel
FtsZ inhibitor with potent and selective in vitro bactericidal activ-
ity against methicillin-susceptible Staphylococcus aureus (MSSA)
methicillin-resistant Staphylococcus aureus (MRSA).
Methods & Materials: The antibacterial activities were deter-
mined by the CLSI micro-broth dilution methods. In vivo efﬁcacy
was evaluated in mouse model of infection caused by MRSA.
Results: Compound-A showed potent activity against various
clinical isolates of MSSA and MRSA. The MIC90s of Compound-
A against MRSA was 2g/mL, respectively. Compound-A showed
the potent inhibitory activity against S. aureus FtsZ enzyme >100
fold selection against its mammalian homolog porcin -tubulin.
Compound- A showed bactericidal activity against MRSA and
showed synergy with carbapenem drugs. Compound-A was efﬁ-
cacious in mouse infection model.
Conclusion: Compound-A showed potent activity against mul-
tidrug resistantMRSAstrainsandbactericidal activity. These results
suggest that Compound-A is suitable for further investigation.
http://dx.doi.org/10.1016/j.ijid.2016.02.318
